Related Experiment Videos
Methodological issues in papers on IFN therapy: time for reappraisal
L A Kondili1, G Taliani, M E Tosti
1Laboratorio di Epidemiologia e Biostatistica, Istituto Superiore di Sanit¿a, Roma, Italy.
Journal of Viral Hepatitis
|June 10, 2000
Summary
Methodological standards for interferon (IFN) therapy trials in chronic hepatitis C are inconsistent. Review of 194 papers reveals varied study designs and response criteria, impacting result reliability.
Area of Science:
- Hepatology
- Clinical Trial Methodology
- Virology
Background:
- Interferon (IFN) therapy has been a cornerstone treatment for chronic hepatitis C.
- Evaluating the efficacy and response predictors of IFN therapy is crucial for clinical practice.
- Methodological inconsistencies in clinical trials can hinder the interpretation and comparison of study findings.
Purpose of the Study:
- To analytically review the methodology of studies evaluating interferon (IFN) therapy for chronic hepatitis C.
- To assess study designs, efficacy evaluation criteria, and response predictors in published IFN therapy trials.
- To identify areas for improvement in the design and reporting of clinical trials for antiviral therapies.
Main Methods:
- Analytical review of 194 full-text papers on interferon (IFN) therapy for chronic hepatitis C.
- Categorization of studies into randomized controlled trials (RCTs), non-randomized controlled trials (NRCTs), and observational studies (OS).
- Focused methodological analysis on clinical trials, examining enrollment criteria, sample size, response calculation, outcome measures, and predictor evaluation.
Main Results:
- Of 194 papers, 64 were RCTs, 40 NRCTs, and 90 OS. Uniform enrollment criteria were used in less than 50% of trials.
- Only 20% of RCTs and 2.5% of NRCTs used sample size criteria. Response rates were not consistently calculated on an intention-to-treat basis.
- Treatment outcomes and response criteria lacked standardization; alanine aminotransferase (ALT) normalization was the sole marker in over 50% of trials, with histological evidence considered in only 57.6% of clinical trials.
Conclusions:
- Significant methodological variability exists in chronic hepatitis C interferon (IFN) therapy trials.
- Lack of standardized criteria for study design, patient enrollment, and response assessment compromises the reliability of trial results.
- Adherence to basic methodological requirements is essential for future antiviral therapy trials to ensure comparable and combinable findings.